Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02884726 | Phase 1 Study of Mesothelin-ADC | PHASE1 | COMPLETED | 8 | — | — | Oct 14, 2016 | Sep 6, 2017 | Mar 19, 2020 | 1 | Japan |
AEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
SAEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
AE leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
SAEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
| Arm | Type | Description |
|---|---|---|
| BMS-986148 intravenous infusion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986148 | DRUG | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Must have histological confirmation of advanced and/or metastatic solid tumors which are expected to express mesothelin * Must have received and either pro...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |